The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Andersen, Fred ^a   Viitanen, Matti ^b   Halvorsen, Dag S ^c,d   Straume, Bjørn ^a   Wilsgaard, Tom ^a   Engstad, Torgeir A ^d  

^a UNIVERSITY OF TROMSØ   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Alzheimer's disease; Postponement of cognitive deterioration; Symptomatic treatment

Indexed keywords

DONEPEZIL; PLACEBO;

AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BARTHEL INDEX; COGNITION; COGNITIVE DEFECT; COMMUNITY CARE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DSM-IV-TR; EDUCATIONAL STATUS; FACTORIAL DESIGN; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NAUSEA; NERVE STIMULATION; NIGHTMARE; NURSING HOME PATIENT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RURAL POPULATION; SEMI STRUCTURED INTERVIEW; SOCIAL INTERACTION; SOCIAL SUPPORT; STRUCTURED QUESTIONNAIRE; TASK PERFORMANCE; WALKING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COMBINED MODALITY THERAPY; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; NORWAY; PHYSICAL THERAPY MODALITIES; PIPERIDINES; PREVALENCE; TREATMENT OUTCOME;

EID: 84867925927     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-59     Document Type: Article

References (33)

1. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009, 24(Suppl 2):95-121.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031. 10.1016/S0140-6736(10)61349-9, 21371747.
3. Golden J, Lawlor B. Treatment of dementia in the community. BMJ 2006, 333:1184-1185. 10.1136/bmj.39051.484421.80, 1693638, 17158363.
4. Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev 2003, 4:CD003260.
5. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004, 85:1694-1704. 10.1016/j.apmr.2004.03.019, 15468033.
6. Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefnagels WH, Rikkert MG. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 2006, 333:1196. 10.1136/bmj.39001.688843.BE, 1693594, 17114212.
7. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 2000, 4:CD001190.
8. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008, 148:379-397.
9. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003, 289:210-216. 10.1001/jama.289.2.210, 12517232.
10. Requena C, Maestu F, Campo P, Fernandez A, Ortiz T. Effects of cholinergic drugs cognitive training on dementia: 2-year follow-up. Dement Geriatr Cogn Disord 2006, 22:339-345. 10.1159/000095600, 16954689.
11. Matsuda O. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. Int Psychogeriatr 2007, 19:241-252. 10.1017/S1041610206004194, 17005066.
12. Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. J Speech Lang Hear Res 2004, 47:1149-1163. 10.1044/1092-4388(2004/085), 15603468.
13. Andersen F, Engstad T, Straume B, Viitanen M, Halvorsen DS, Hykkerud S, Sjøbrernd K. Recruitment methods in Alzheimer's disease research: general practice versus population based screening by mail. BMC Med Res Methodol 2010, 10:35-42. 10.1186/1471-2288-10-35, 2880123, 20429946.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
15. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989, 19:1015-1022. 10.1017/S0033291700005742, 2594878.
16. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989, 37:725-729.
17. Dratcu L, da Costa RL, Calil HM. Depression assessment in Brazil. The first application of the Montgomery-Asberg Depression Rating Scale. Br J Psychiatry 1987, 150:797-800. 10.1192/bjp.150.6.797, 3651734.
18. Bebbington P. Welcome to ICD-10. Soc Psychiatry Psychiatr Epidemiol 1992, 27:255-257.
19. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746. 10.1016/S1474-4422(07)70178-3, 17616482.
20. Burch EA, Andrews SR. Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med 1987, 17:193-200. 10.2190/GCVN-D2LJ-APH3-KN0K, 3610485.
21. Stone SP, Ali B, Auberleek I, Thompsell A, Young A. The Barthel index in clinical practice: use on a rehabilitation ward for elderly people. J R Coll Physicians Lond 1994, 28:419-423.
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314. 10.1212/WNL.44.12.2308, 7991117.
23. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 2010, 6:39-53. 10.1016/j.jalz.2009.05.665, 19592311.
24. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994, 151:390-396.
25. Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 2003, 183:248-254. 10.1192/bjp.183.3.248, 12948999.
26. Metitieri T, Zanetti O, Geroldi C, Frisoni GB, De LD, Dello BM, et al. Reality orientation therapy to delay outcomes of progression in patients with dementia. A retrospective study. Clin Rehabil 2001, 15:471-478.
27. Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del ST, et al. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 2010, 30:161-178. 10.1159/000316119, 20838046.
28. Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials 2010, 7:246-255. 10.1177/1740774510367916, 20421243.
29. Wickstrom G, Bendix T. The "Hawthorne effect"-what did the original Hawthorne studies actually show?. Scand J Work Environ Health 2000, 26:363-367. 10.5271/sjweh.555, 10994804.
30. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised controlled trial. BMC Medical Research Methodology 2006, 7:30-37.
31. Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011, 36:339-354. 10.1038/npp.2010.81, 3055515, 20592717.
32. Dumitriu A, Popescu BO. Placebo effects in neurological diseases. J Med Life 2010, 3:114-121. 3019048, 20968195.
33. Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA. Co-morbidity and drug treatment in Alzheimer`s disease. A cross sectional study of participants in the Dementia study in Northern Norway. BMC Geriatric 2011, 11:58-65.